Pursuing non-surgical larynx preservation for advanced disease carries a high functional cost. Even in successful cases at top centers, nearly half the patients end up with a permanent tracheostomy, and a quarter suffer from chronic aspiration, undermining the primary goal of maintaining quality of life.

A meta-analysis of six trials (Poseidon) found no overall survival benefit from adding long-course (24 months) hormone therapy to post-operative radiotherapy. It suggests that a shorter course of 4-6 months is adequate for most men, marking a significant shift towards treatment de-escalation to reduce long-term toxicity without compromising efficacy in this specific setting.

Using radiation as a consolidation therapy after chemo has a significant downside. It damages local tissue, limiting future surgical options and often precluding a neobladder reconstruction—a major quality-of-life factor for patients who may relapse later and require surgery.

In survivors over 50, an increased risk of secondary cancers is specifically associated with prior radiation treatment received 30+ years ago. The study found no similar association with chemotherapy exposures, highlighting the exceptionally long-term and distinct risks of radiation. This underscores the importance of modern efforts to reduce or eliminate its use.

The SUNRISE 2 trial's chemoradiation arm showed unexpectedly strong results. This is likely due to a protocol requiring a repeat resection (RIT-URBT) before randomization, which weeded out aggressive tumors and selected a patient population with a better prognosis, making the control arm unusually difficult to beat.

The chemoradiation control arm in SUNRISE 2 performed so well (e.g., 95% 1-year overall survival) that it challenges the long-held belief that surgery is unequivocally superior. This result, alongside other recent studies, suggests chemoradiation should be considered a potent standard-of-care contender for bladder preservation in appropriately selected patients.

Despite being the backbone for new combination therapies in trials like Matterhorn, the FLOT chemotherapy regimen has significant toxicity. Approximately 30% of patients discontinue treatment due to adverse events, and only half manage to complete the post-surgery adjuvant portion, posing a major clinical challenge in real-world settings.

New bladder-sparing trials mandate nine cycles of EV-Pembro to replicate the conditions of successful surgical trials. This conservative approach ignores that patient response is front-loaded while toxicity is back-loaded, likely overtreating many patients to ensure comparable efficacy.

The HN009 trial challenged the standard high-dose cisplatin regimen for head and neck cancer. While weekly cisplatin reduced expected hearing and kidney toxicity, it unexpectedly caused more bone marrow toxicity. The overall "toxicity score" showed no difference between arms for HPV-positive patients, halting the trial's progression.